Lipocine announced that study enrollment is complete and the first cohort of subjects has been dosed in pivotal pharmacokinetic study designed to support a New Drug Application for LPCN 1154. LPCN 1154, oral brexanolone, is being developed by Lipocine for the treatment of postpartum depression.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LPCN:
- Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
- Lipocine Inc (LPCN) Q4 Earnings Cheat Sheet
- Lipocine Announces Key Study Dosing for Postpartum Depression Treatment
- Lipocine confirms dosing regimen for pivotal study of LPCN 1154
- Lipocine to continue commercialization of Tlando through Verity Pharma
